1.055

1.40% -0.015

Achilles Therapeutics Plc Adr (ACHL)

Overview News Price History Discussions Forecast

Achilles Therapeutics Plc Adr stock is traded at $1.055, with a volume of 13,516. It is down -1.40% in the last 24 hours and up +6.35% over the past month. Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Previous Close:

$1.07

Open:

$1.0505

24h Volume:

13,516

Relative Volume:

0.02

Market Cap:

$43.55M

Revenue:

Net Income/Loss:

$-66.88M

P/E Ratio:

-0.5861

EPS:

-1.8

Net Cash Flow:

$-62.91M

1W Performance:

-1.40%

1M Performance:

+6.35%

6M Performance:

+11.78%

1Y Performance:

+31.06%

1-Day Range:

$1.05

$1.06

1-Week Range:

$1.01

$1.08

52-Week Range:

$0.63

$1.76

Achilles Therapeutics Plc Adr Stock (ACHL) Company Profile

Name

Achilles Therapeutics Plc Adr

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

Address

Employee

215

Twitter

Next Earnings Date

2024-12-11

Latest SEC Filings

ACHL's Discussions on Twitter

Compare ACHL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACHL	1.055	43.55M	0	-66.88M	-62.91M	-1.80
VRTX	447.13	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	744.63	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	592.30	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.53	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	104.04	24.49B	3.30B	-501.07M	1.03B	11.54

Achilles Therapeutics Plc Adr Stock (ACHL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	Chardan Capital Markets	Buy
Apr-26-21	Initiated	JP Morgan	Underweight
Apr-26-21	Initiated	Oppenheimer	Outperform
Apr-26-21	Initiated	Piper Sandler	Overweight

Achilles Therapeutics Plc Adr Stock (ACHL) Latest News

Nov 19, 2024

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market - GlobeNewswire Inc.

Nov 19, 2024

Oct 16, 2024

80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港

Oct 16, 2024

Sep 23, 2024

ACHL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Sep 23, 2024

Check Out Achilles Therapeutics Plc ADR (ACHL)’s Trade Data Rather Than the Analysts’ Views - SETE News

Sep 23, 2024

Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Sep 23, 2024

Sep 20, 2024

why Achilles Therapeutics Plc ADR [ACHL] is a Good Choice for Investors After New Price Target of $1.25 - The DBT News

Sep 20, 2024

What Analysts Were Expecting After PowerFleet Inc (NASDAQ: AIOT) rose 2.40% - Stocks Register

Sep 20, 2024

Achilles Thera shifts focus to new cancer treatment avenues - The Pharma Letter

Sep 20, 2024

Sep 19, 2024

Achilles Therapeutics ends TIL-based cancer therapy trials - Investing.com

Sep 19, 2024

You Should Read This Analysis Before Investing in Achilles Therapeutics Plc ADR (NASDAQ:ACHL) - US Post News

Sep 19, 2024

Achilles stock climbs on strategic focus (NASDAQ:ACHL) - Seeking Alpha

Sep 19, 2024

Achilles Therapeutics Announces Strategic Update - Yahoo Finance

Sep 19, 2024

Aug 14, 2024

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire

Aug 14, 2024

Jun 27, 2024

Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why - Yahoo New Zealand News

Jun 27, 2024

Jun 24, 2024

Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why - Yahoo Sport Australia

Jun 24, 2024

Jun 19, 2024